July 2024
AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations
AstraZeneca, IRA, Medicare, Drug Price Negotiation, Constitutional Challenge, Appeal
Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data
Roche, Carmot Therapeutics, GLP-1/GIP receptor agonist, CT-388, obesity treatment, weight loss, diabetes, pharmaceutical industry
Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development
Asceneuron, Series C Funding, Dementia Asset, Novo Ventures, Biotech Investment
CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications
CordenPharma, GLP-1, peptide manufacturing, expansion, investment, diabetes, obesity, pharmaceutical industry
Vertex Pharmaceuticals Sues US Government Over Fertility Assistance Program for Gene Therapy Patients
Vertex Pharmaceuticals, gene therapy, fertility assistance program, lawsuit, US government, health insurance, fertility preservation
Lexeo Therapeutics Reports Promising Early Data for Gene Therapy LX2006 in Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics, LX2006, Gene Therapy, Friedreich Ataxia, Cardiomyopathy, Clinical Trials, Rare Genetic Disorders
GSK Headquarters Returns to Central London
GSK, Global Headquarters, Central London, The Earnshaw, Sustainability, Hybrid Working
Artiva Biotherapeutics Seeks $116M in Second IPO Attempt for Cell Therapy Development
Artiva Biotherapeutics, IPO, cell therapy, AlloNK, systemic lupus erythematosus, autoimmune diseases
Congress Must Reauthorize FDA Program for Pediatric Rare Diseases to Save Lives
Pediatric Rare Diseases, FDA Program, Reauthorization, Creating Hope Act, Priority Review Voucher Program
Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?
Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition